WO2007091253A3 - Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels - Google Patents
Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels Download PDFInfo
- Publication number
- WO2007091253A3 WO2007091253A3 PCT/IL2007/000155 IL2007000155W WO2007091253A3 WO 2007091253 A3 WO2007091253 A3 WO 2007091253A3 IL 2007000155 W IL2007000155 W IL 2007000155W WO 2007091253 A3 WO2007091253 A3 WO 2007091253A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clopidogrel
- vitamins
- pharmaceutical compositions
- homocysteine levels
- vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions comprising a combination of clopidogrel and one or more vitamins for reducing blood homocysteine levels, such as folic acid, a pyridoxine salt, preferably pyridoxine hydrochloride (vitamin B6), and cyanocobalamin (vitamin B12), are useful in the treatment or prevention of pathologies induced by platelet aggregation, preferably cardiovascular, peripheral vascular or homocysteine related disorders or diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76520006P | 2006-02-06 | 2006-02-06 | |
US60/765,200 | 2006-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007091253A2 WO2007091253A2 (en) | 2007-08-16 |
WO2007091253A3 true WO2007091253A3 (en) | 2009-04-09 |
Family
ID=38345539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2007/000155 WO2007091253A2 (en) | 2006-02-06 | 2007-02-06 | Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007091253A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104001176B (en) * | 2014-06-11 | 2016-06-22 | 深圳奥萨医药有限公司 | The pharmaceutical composition of platelet ADP receptor antagonist and vitamin B group |
CN113456821A (en) * | 2021-07-01 | 2021-10-01 | 苏州大学 | Combined pharmaceutical composition for preventing cardiovascular diseases complicated by hypertension and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429210B1 (en) * | 1998-06-15 | 2002-08-06 | Sanofi-Synthelabo | Polymorphic clopidogrel hydrogenesulphate form |
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
-
2007
- 2007-02-06 WO PCT/IL2007/000155 patent/WO2007091253A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429210B1 (en) * | 1998-06-15 | 2002-08-06 | Sanofi-Synthelabo | Polymorphic clopidogrel hydrogenesulphate form |
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
Also Published As
Publication number | Publication date |
---|---|
WO2007091253A2 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259851A (en) | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | |
IL189578A (en) | Pyridine derivatives, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments for the treatment of cns disorders | |
WO2006044101A3 (en) | Method and composition for supplementation of nutritional deficiencies in renal patients | |
IL206296A (en) | Aminopyrazole derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for prevention or treatment of diseases | |
WO2006120682A3 (en) | Compositions and methods for treating hyperproliferative epidermal diseases | |
MY148723A (en) | Use of pinolenic acid for the treatment of obesity | |
WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
WO2007027761A3 (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
IL207038A (en) | Diazaspiro[5.5]undecane derivatives, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for treating or reducing the risk of an inflammatory disease or condition | |
IL197128A (en) | Pyridone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for influencing eating behavior | |
MX2013000319A (en) | Treatment of cognitive disorders. | |
WO2007041368A3 (en) | Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection | |
WO2009134086A3 (en) | Pharmaceutical formulation for treatment of cardiovascular disease | |
CY1112547T1 (en) | Means Containing Folic Acid, Vitamin B6 And Vitamin B12, And Their Use | |
EP2012807A4 (en) | Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders | |
WO2007093880A3 (en) | Novel pyrone-indole derivatives and process for their preparation | |
WO2008029237A3 (en) | Combination therapies for rheumatoid arthritis | |
WO2008094825A3 (en) | Compositions and methods for maintaining, strengthening, improving or promoting eye health | |
WO2012125981A3 (en) | Raf kinase inhibitors | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2009010810A3 (en) | Cardiovascular combinations comprising ace and hmg-co-a inhibitors | |
WO2006128048A3 (en) | Methods and compositions for reducing blood homocysteine levels | |
WO2009118726A3 (en) | Oral combination of vitamins | |
WO2008010008A3 (en) | Cardiovascular combinations using rennin-angiotensin inhibitors | |
WO2007091253A3 (en) | Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07706098 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07706098 Country of ref document: EP Kind code of ref document: A2 |